Asahi Kasei Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Koshiro Kudo
- Full Time Employees
- 47,895
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Hibiya Mitsui Tower Tokyo TY Japan 100-0006
- IPO Date
- May 16, 1949
- Website
- asahi-kasei.co.jp
- Similar Companies
- Business
- Asahi Kasei Corp. (3407.T) manufactures and sells advanced materials, homes, and healthcare products worldwide. The company operates through three primary business sectors: Materials, which encompasses basic chemicals, performance products including fibers and engineering plastics such as LEONA polyamide resin and TENAC polyacetal, specialty solutions, and electronics components like Hall effect sensors, lithium-ion battery separators under the Hipore brand, and semiconductor materials; Homes, centered on Hebel Haus unit homes, Hebel autoclaved aerated concrete panels, Neoma Foam phenolic foam insulation, foundation systems, and steel-frame structural components; and Healthcare, providing medical devices for blood purification and transfusion such as Planova virus removal filters, critical care equipment including defibrillators and automated CPR systems, pharmaceuticals in orthopedics and urology, bioprocess products, and diagnostic reagents. Founded in 1931 and headquartered in Tokyo, Japan, Asahi Kasei maintains manufacturing facilities and sales operations across Japan, North America, Europe, Asia, and other regions, serving industries including automotive, construction, electronics, and medical care. In recent developments, the company divested its Daramic lead-acid battery separator business to Kingswood Capital Management on December 1, 2025, as part of its medium-term management plan "Trailblaze Together" to enhance capital efficiency and focus on growth areas like pharmaceuticals, critical care, overseas homes, and electronics; announced an absorption-type merger on December 2, 2025, between its wholly owned subsidiary Asahi Kasei Advance and Teijin Frontier, forming a joint venture effective October 1, 2026, with Asahi Kasei holding 20% to integrate business platforms in sustainable fibers; completed the acquisition of Calliditas Therapeutics AB in September 2024, bolstering its global specialty pharmaceuticals presence in renal and autoimmune diseases; and acquired shares in R.C. Core Co., Ltd. through Asahi Kasei Homes in October 2025.
Company News
Asahi Kasei (OTCMKTS:AHKSY) Stock Price Down 4.5% – Should You Sell?
Asahi Kasei Corp. (OTCMKTS:AHKSY) Sees Large Increase in Short Interest
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
US FDA approves Asahi Kasei's drug for persistent herpes infections
Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements
Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
Best Value Stocks to Buy for April 30th
New Strong Buy Stocks for April 30th
5 Undervalued Price-to-Sales Stocks That Could Deliver Outsized Gains
Critical Comparison: Asahi Kasei (OTCMKTS:AHKSY) vs. TOR Minerals International (OTCMKTS:TORM)